100861-94-7

Basic information

• Product Name: 1-(3,4-DIMETHOXYBENZYL)PIPERIDIN-4-AMINE
• Synonyms: 1-(3,4-DIMETHOXYBENZYL)PIPERIDIN-4-AMINE
• CAS NO: 100861-94-7
• Molecular Formula: C₁₄H₂₂N₂O₂
• Molecular Weight: 250.33668
• Mol File: 100861-94-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 351.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.081±0.06 g/cm3(Predicted)
• PKA: 10.10±0.20(Predicted)
• CAS DataBase Reference: 1-(3,4-DIMETHOXYBENZYL)PIPERIDIN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DIMETHOXYBENZYL)PIPERIDIN-4-AMINE(100861-94-7)
• EPA Substance Registry System: 1-(3,4-DIMETHOXYBENZYL)PIPERIDIN-4-AMINE(100861-94-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 100861-94-7(Hazardous Substances Data)

Usage

General Description

1-(3,4-dimethoxybenzyl)piperidin-4-amine is a chemical compound with the molecular formula C16H24N2O2. It is a piperidine derivative with a benzyl group and two methoxy groups attached to the benzene ring. The compound has potential pharmaceutical applications and may be used in the development of new medications. Its chemical structure and properties make it of interest for further research in the fields of medicinal chemistry and drug discovery. Additionally, it may have the potential for use as a building block in organic synthesis or as a reagent in various chemical reactions. Overall, the compound has potential for various applications in the field of pharmaceuticals and chemical synthesis.

Upstream product

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 21852-32-4 4-bromomethyl-1,2-dimethoxybenzene 

Downstream Products

• 76167-76-5 [1-(3,4-Dimethoxy-benzyl)-piperidin-4-yl]-pyrimidin-2-yl-amine 

Relevant articles and documents

Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3- b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors

Janus kinase 1 (JAK1) plays a key role in most cytokine-mediated inflammatory and autoimmune responses through JAK/STAT signaling; thus, JAK1 inhibition is a promising therapeutic strategy for several diseases. Analysis of the binding modes of current JAK inhibitors to JAK isoforms allowed the design of N-alkyl-substituted 1-H-pyrrolo[2,3-b] pyridine carboxamide as a JAK1-selective scaffold, and the synthesis of various methyl amide derivatives provided 4-((cis-1-(4-chlorobenzyl)-2-methylpiperidin-4-yl)amino)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (31g) as a potent JAK1-selective inhibitor. In particular, the (S,S)-enantiomer of 31g (38a) exhibited excellent potency for JAK1 and selectivity over JAK2, JAK3, and TYK2. On investigating the effect of 31g on hepatic fibrosis, it was found that it reduces the proliferation and fibrogenic gene expression of TGF-β-induced hepatic stellate cells (HSCs). Specifically, 31g significantly inhibited TGF-β-induced migration of HSCs at 0.25 μM in wound-healing assays.

Dopaminergic activity in a series of N-substituted 2-aminopyrimidines

-